A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety

NCT06070597 | Completed Phase 1

• 2 other identifiers: 1346-00512023-504693-38-00
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the effects of iclepertin in the range of therapeutic to supra-therapeutic exposures on the (QT/QTc): Electrocardiogram (ECG) time interval from the start of the QRS complex (ECG time interval) to the end of the T wave / QT interval corrected for heart rate, e.g. using the method of Fridericia or Bazett interval and other ECG parameters.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• QTcF change from baseline matched to the plasma concentration of iclepertin collected at the same time point

  QT interval corrected for heart rate, e.g. using the method of Fridericia (QTcF).

  Up to 12 days

Secondary Outcomes (1)

• QTcF change from baseline matched to the plasma concentration of moxifloxacin collected at the same time point

  Up to 1 day

Study Arms (3)

Arm 1: Iclepertin treatment+ Placebo to Moxifloxacin

EXPERIMENTAL

Placebo to moxifloxacin (Day 1) + Iclepertin (Day 1-12) + Placebo to moxifloxacin (Day 13

Drug: Iclepertin; Drug: Moxifloxacin Placebo

Arm B1: Iclepertin Placebo treatment + Moxifloxacin

EXPERIMENTAL

Moxifloxacin (Day 1) + Placebo to iclepertin (Day 1-12) + Placebo to moxifloxacin (Day 13) - Arm B1

Drug: Iclepertin Placebo; Drug: Moxifloxacin; Drug: Moxifloxacin Placebo

Arm B2: Iclepertin Placebo treatment + Placebo to Moxifloxacin

EXPERIMENTAL

Placebo to moxifloxacin (Day 1) + Placebo to iclepertin (Day 1-12) + Moxifloxacin (Day 13) - Arm B2

Drug: Iclepertin Placebo; Drug: Moxifloxacin; Drug: Moxifloxacin Placebo

Interventions

Iclepertin DRUG

Iclepertin

Arm 1: Iclepertin treatment+ Placebo to Moxifloxacin

Iclepertin Placebo DRUG

Placebo to Iclepertin

Arm B1: Iclepertin Placebo treatment + Moxifloxacin; Arm B2: Iclepertin Placebo treatment + Placebo to Moxifloxacin

Moxifloxacin DRUG

Moxifloxacin

Arm B1: Iclepertin Placebo treatment + Moxifloxacin; Arm B2: Iclepertin Placebo treatment + Placebo to Moxifloxacin

Moxifloxacin Placebo DRUG

Placebo Moxifloxacin

Arm 1: Iclepertin treatment+ Placebo to Moxifloxacin; Arm B1: Iclepertin Placebo treatment + Moxifloxacin; Arm B2: Iclepertin Placebo treatment + Placebo to Moxifloxacin

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, ital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests without clinically significant abnormalities
• Age of 18 to 50 years (inclusive)
• Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
• Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
• Either male subject, or female subject who meets any of the following criteria for a highly effective contraception from at least 30 days before the first administration of trial medication until 30 days after trial completion:
• Use of combined (estrogen and progestogen containing) hormonal contraception that prevents ovulation (oral, intravaginal, subdermal or transdermal), plus condom
• Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants), plus condom
• Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
• Sexually abstinent
• A vasectomized sexual partner who received medical assessment of the surgical success (documented absence of sperm) and provided that partner is the sole sexual partner of the trial participant
• Surgically sterilized (including hysterectomy)
• Postmenopausal, defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of Follicle stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L (or the reference range from the local safety laboratory) is confirmatory), hormone replacement therapy is not permitted Note: Male subjects are not required to use contraception.

You may not qualify if:

• Subjects will not be allowed to participate, if any of the following general criteria apply:
• Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
• Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
• Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, in particular, hepatic parameters (Alanine transaminase (ALT), Aspartate aminotransferase (AST), total bilirubin) or renal parameters (creatinine) exceeding the Upper limit of normal (ULN)
• Any evidence of a concomitant disease assessed as clinically relevant by the investigator
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
• Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
• History of relevant orthostatic hypotension, fainting spells, or blackouts

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (1)

CRS Clinical Research Services Mannheim GmbH

Mannheim, 68167, Germany

Location

Related Links

• Related Info

MeSH Terms

Interventions

Moxifloxacin

Intervention Hierarchy (Ancestors)

Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: A double-blind, randomised, placebo-controlled, multiple-dose, parallel group with nested crossover design trial, with moxifloxacin as positive control

Study Record Dates

• First Submitted: October 2, 2023
• First Posted: October 6, 2023
• Study Start: January 25, 2024
• Primary Completion: June 5, 2024
• Study Completion: June 5, 2024
• Last Updated: July 9, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)